Cannabis Supply Agreement Terms for Canadian LPs in 2026

Export deals usually arrive as a term sheet. Product, volume, price, and a target first-shipment date, all on one page. That page is not the agreement. The document set that governs the relationship has three layers, and the money sits in the last two.

The master agreement carries the commercial frame: term, territory, order and forecast mechanism, payment, liability, termination, and governing law. Annexed to it sits the product specification, which defines what you are actually selling, and a quality or technical agreement, which allocates regulatory duties between you and the importer. Pharmaceutical supply chains have used that structure for decades. Medical cannabis inherited it, and any importer holding an EU-GMP authorisation will expect to see it.

None of it matters until both sides survive diligence. Importers will ask for your licence, your Health Canada inspection history, batch records, and testing data, and you should be running the same exercise in reverse on them. Our guide to vetting a Canadian Licensed Producer sets out what serious buyers check, which doubles as a checklist for what you should be checking about a new counterparty.

One caveat, stated plainly: this is commercial guidance, not legal advice. Contract law, agency rules, and distributor protections differ market to market, so a lawyer admitted in the destination country should read the final draft before anyone signs. Signing a term sheet before the annexes exist is the most reliable way to end up supplying against a specification you never agreed to.

The specification annex is the only part of the agreement a quality manager reads twice. It decides whether a pallet that lands in Frankfurt gets released or quarantined. It also decides who pays when the answer is quarantined.

The four-point specification test

Run every line of the annex through four questions:

• Is the attribute measurable rather than descriptive?
• Is the test method named?
• Do the limits match the destination market, not the Canadian one?
• Is there a stated tolerance?

A line that fails any of the four is a future argument with a delivery date attached.

Cannabinoid content belongs in the annex as a range with a tolerance, never as a single target number, because flower drifts between harvests and nobody wins a fight over one percentage point. Water activity and moisture belong there too, since they drive microbial risk and shipped weight at the same time. Microbial, heavy metal, and pesticide limits should be written to the destination standard: TGO 93 for Australia, European Pharmacopoeia methods for EU importers, plus whatever sits in the importer's own release specification on top. Our breakdown of contaminant testing limits across export markets covers where those thresholds diverge, and our comparison of testing requirements across four export markets shows which panels each destination actually demands.

Then there is appearance, which is where contracts get lazy. "Premium", "large-bud", and "hand-trimmed" carry no measurable meaning on their own. Most rejections are not potency disputes at all. They are visual-grading disputes, and they are avoidable with a photographic reference standard, a measured minimum bud dimension, and an agreed trim standard attached to the annex.

Testing rights are the other half of the clause. Name the laboratory, the accreditation, the sampling plan, and whose result governs when two laboratories disagree. ISO/IEC 17025 accreditation is the baseline importers expect, and a referee laboratory clause costs nothing to add while it settles an argument that would otherwise run for weeks. Every batch travels with a certificate of analysis, and if the importer's quality team cannot read yours the way you read it, you have a documentation problem rather than a product problem. Our certificate of analysis guide walks through how B2B buyers work the panels.

Rejection mechanics deserve their own paragraph. Set a notice window that starts on a defined event, require any rejection to cite a specific failed parameter with a supporting result, and decide in advance what happens to product that fails. That last point is where optimism meets narcotics law. Failed product rarely comes home, because a return shipment means the importer needs an export authorisation and you need an import permit, for goods nobody wants to pay for twice. Witnessed destruction at destination is usually cheaper, so agree who funds it while everyone is still friendly.

Germany removed medical cannabis from its narcotics schedule in 2024. Order volumes followed, and the binding constraint shifted from demand to paperwork. Your agreement has to say who absorbs that.

Every shipment needs its own export permit. Under the Cannabis Act and the Cannabis Regulations, Health Canada issues export permits shipment by shipment, and it expects to see the import authorisation from the destination country's competent authority before it does. A signed twelve-month agreement does not shorten that queue. It guarantees you will stand in it twelve times.

The competent authority changes by market. German narcotic import permits come from the Bundesopiumstelle, the federal opium agency that sits inside BfArM, and our guide to the narcotic import permit sequence sets out how the two permits have to line up. Australian imports run through the licence and permit system operated by the Office of Drug Control, with TGO 93 governing the product itself. Israeli shipments answer to the Israel Medical Cannabis Agency and its IMC-GMP requirements. Our walkthrough of the Health Canada export permit process covers the Canadian half step by step.

Three drafting points follow. First, delivery windows should run from the date the last required permit issues, not from the purchase order date, because a window that starts on the order date hands permit risk to the party with the least control over it. Second, standard force majeure wording rarely captures administrative delay at a regulator, so name regulatory processing delay in the clause rather than hoping a court reads it in. Third, decide up front who pays for storage, re-testing, and demurrage when a container sits at customs while a permit gets amended.

Incoterms carry more weight here than in ordinary trade. Incoterms 2020 allocates cost and risk, but a controlled-substance shipment adds a licensing layer on top: the party arranging carriage has to be the party whose authorisations cover that movement. FCA or CIP terms, with the importer's licensed forwarder collecting the goods, usually match the permit structure better than a delivered-at-place promise you cannot lawfully perform. Match the Incoterm to whoever holds which licence, then price the freight into the deal instead of discovering it later.

Currency is the first place a good margin quietly disappears. Price in euros or Australian dollars and you carry the exchange exposure. Price in Canadian dollars and the importer carries it. Neither side enjoys losing that argument, which is why a band beats a winner: fix the price in one currency and let either party reopen it if the rate moves past an agreed percentage for an agreed period.

Volume language matters more than the volume number. A rolling forecast is a planning tool, not a commitment, and holding cultivation rooms against a non-binding forecast is unpaid risk carried by the producer. If an importer wants reserved capacity, that is a take-or-pay commitment or a reservation fee, not a courtesy. Firm quantities belong on purchase orders, issued with enough lead time to harvest against.

Payment terms should track the release timeline. EU importers commonly perform their own quality control and market release after goods land, and they will ask to pay on release rather than on delivery. A workable middle: payment on delivery against documents, a retention percentage held back until release, and a hard outside date after which the retention becomes payable regardless of where the release sits.

Which brings up exclusivity, the term most often given away for nothing. The plain version: never grant territory-wide exclusivity to an importer who has not yet cleared a batch through customs and paid for it. Forecasts and reputation are not performance. Where exclusivity is genuinely earned, bound it four ways, by named cultivars, defined territory, fixed term, and volume thresholds that convert the arrangement to non-exclusive automatically when they are missed. Then add termination rights for regulatory cause on either side, for repeated specification failures, and for change of control, and state what happens to goods already in transit when notice is served.

AlphaLeaf grows indoor cannabis flower in Montreal as a Health Canada Licensed Producer, with refined genetics, hand-trimmed finishing, and ISO-certified batch testing behind every lot. We hold export authorisation under the Cannabis Act and keep the traceability and documentation records that German, Australian, and Israeli buyers ask for during supplier qualification. We prefer to open a conversation with the specification annex, because that is the page where a supply relationship is actually decided.

If you are drafting or renegotiating supply for Canadian-origin flower, send us the specification you need to hit and we will tell you plainly whether we can hold it batch after batch. Contact the AlphaLeaf team to start there. Bring the annex. That is the real document.

What is a cannabis supply agreement?

A cannabis supply agreement is a master contract between a Licensed Producer and an importer or distributor that sets the product specification, order and forecast mechanism, price, currency, delivery terms, quality obligations, and rejection rights. Individual shipments are then placed as purchase orders under that framework, each one carrying its own permits.

Does a supply agreement replace a Health Canada export permit?

No. Health Canada issues cannabis export permits shipment by shipment, and it expects to see the destination country's import authorisation before issuing one. A supply agreement commits both parties commercially, but every shipment under it still needs its own permits on the Canadian side and the import side.

Who decides whether a batch fails specification?

Whoever the contract says. Without a named referee laboratory, both parties test independently and then argue. Name the accredited laboratory, the sampling plan, the test methods, and whose result governs a dispute, and set a notice window that requires the rejecting party to cite the specific parameter that failed.

Should a Canadian LP grant an importer exclusivity?

Not before that importer has cleared a shipment through customs and paid for it. Where exclusivity is warranted, limit it to named cultivars, a defined territory, and a fixed term, with volume thresholds that convert it to a non-exclusive arrangement automatically if the importer misses them.

What currency should an international cannabis supply agreement use?

The pricing currency decides who carries exchange risk. Pricing in euros or Australian dollars moves it to the Canadian producer, while pricing in Canadian dollars moves it to the importer. A reopener clause that lets either side renegotiate once the rate moves beyond an agreed band for an agreed period is the more durable answer.

How long should a cannabis supply agreement run?

Twelve to twenty-four months suits most first relationships, with renewal tied to volume performance rather than automatic rollover. Shorter terms let both sides reprice as export markets and pharmacopoeial requirements change. Longer terms make sense once the importer has taken repeat shipments and the specification has held across batches.